Aspire Biopharma Announces $5M Share Buyback Program

The authorization reflects the Board's confidence in the Company's balance sheet strength, the value of its drug development pipeline and supplement business, and the potential value creation from the recently announced Binding Letter of Intent (LOI) to acquire Dura Driver Control Systems (DCS).

"Aspire's strengthened financial position provides us with significant flexibility in executing our capital allocation strategy," said Kraig Higginson, Chief Executive Officer. "The Board's authorization of a $5.0 million share repurchase program further supports our commitment to returning value to shareholders. We remain confident in our future growth trajectory and are committed to generating additional value as we invest in our key product growth drivers, diversify our portfolio through disciplined business development, and opportunistically repurchase shares."

Share Repurchase Program

Under the Repurchase Program, the Board has authorized the Company to repurchase up to $5.0 million of its outstanding shares of common stock from time to time through open market purchases, privately negotiated transactions, block trades, or otherwise, in accordance with applicable federal securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

The Company expects the purchase will be funded through existing cash on hand. The Repurchase Program does not obligate the Company to repurchase any specific number of shares. The timing, manner, price, and amount of any repurchases will be determined at the Company's discretion based on a variety of factors, including the market price of the Company's common stock, general market and economic conditions, the Company's liquidity requirements, applicable legal requirements, and other factors the Board deems relevant.

The Company may enter into one or more plans under Rule 10b5-1 of the Exchange Act to facilitate repurchases. The Repurchase Program has no fixed expiration date and may be modified, suspended, or terminated by the Board at any time without prior notice. Any shares repurchased will be retired and returned to the status of authorized but unissued shares of common stock.

Corporate & Financial Milestones in 2026

Capital Injection: The Company secured $21 million in private placement financing in its February 2026 and April 2026 preferred stock offerings.

Exchange Compliance: Aspire regained compliance with Nasdaq's minimum stockholders' equity requirement in April 2026 and has received confirmation from Nasdaq.

Transformative Acquisition: On April 15, 2026, Aspire entered a Binding Letter of Intent to acquire DCS, a global automotive supplier, for approximately $30 million in cash.

Commitment Letter: The Company secured a Commitment Letter from a leading financial institution of up to $22.5M to finance the proposed acquisition of DCS.

Aspire Biopharma Clinical Pipeline

Sublingual Aspirin: Aspire's lead candidate, a fast-acting high-dose sublingual aspirin for acute heart attacks, showed it could inhibit platelet aggregation in under two minutes-4 to 5 times faster than chewed tablets.

FDA Milestones: The Company plans to file a New Drug Application (NDA) via the 505(b)(2) pathway near the end of 2026 for its lead Aspirin candidate.

Expanded Pipeline: Formulation and development underway for generic sublingual versions of anti-anxiety drug (Xanax®), anti-nausea drug (Zofran®), anti-platelet drug (Plavix®), as well as others

Intellectual Property: The Company now has Patents filed and pending on eleven different drugs and supplements, including the filing of an omnibus patent application with the U.S. Patent and Trademark Office for its sublingual delivery technology for several key drug classes.

Buzz Bomb Subsidiary Expansion

Product Launch: BUZZ BOMB™ officially launched its 50mg sublingual caffeine stick packs in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha).

Buzz Bomb Growth: Launched a new convenience store pack, rebranded with "science-forward" packaging.

Marketing Momentum: Brand ambassador Ashley Paulson achieved a world-record performance at the recent 100-mile Jackpot Ultra Running Festival, driving increased sales and brand awareness.

Retail Partnerships:

National: Partnered with TruLife Distribution to manage and coordinate the sales, distribution and merchandising of BUZZ BOMB™ to retailers nationwide.

Regional: Signed agreements with Interwest Brokerage to scale BUZZ BOMB™'s retail footprint across the grocery, convenience, and alternate channel sectors throughout the Intermountain West.